AbbVie Seeks FDA OK for Rinvoq in Adults With Active Ankylosing Spondylitis

By Colin Kellaher

AbbVie Inc. on Tuesday said it is seeking approval from the U.S. Food and Drug Administration for expanded use of Rinvoq for the treatment of adults with active ankylosing spondylitis.

AbbVie also said it has also filed for European Medicines Agency approval of Rinvoq for adults with active ankylosing spondylitis who have responded inadequately to conventional therapy.

The North Chicago, Ill., biopharmaceutical company said the applications are supported by data from a Phase 2/3 study in which Rinvoq showed significant improvements in signs and symptoms of the chronic, progressive, inflammatory musculoskeletal disease.

Last year, Rinvoq received U.S. and European approval for adults with moderately to severely active rheumatoid arthritis.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

August 25, 2020 10:09 ET (14:09 GMT)

AbbVie (NYSE:ABBV)
Historical Stock Chart
From Mar 2024 to Apr 2024